Azilect
Links shared publicly online about this topic
Can Early Azilect Slow Parkinson's?
webmd.com — “A study suggests that Azilect may slow Parkinson's if started early in the disease, but contradictory data mean the findings aren't definitive.” View full resource at webmd.com
Most Recently Shared on September 23, 2009 at 9:37 pm By:
Can Early Azilect Slow Parkinson's?: A study suggests that Azilect may slow Parkinson's if started early in the .. http://bit.ly/ZOYgi
TEMPO study added support for Azilect in PD patients
news-medical.net — “Teva Pharmaceutical Industries Ltd. and H. Lundbeck A/S (Lundbeck) today announced newly published long-term data on Azilect(rasagiline tablets) from the TEMPO study and its open-label extension. The findings confirm the long-term efficacy, safety and tolerability of Azilect® in patients with Parkinson's disease (PD) and further demonstrate the benefits obtained with early treatment initiation. The data was published in the June 2010 issue of the International Journal of Neuroscience.” View full resource at news-medical.net
Most Recently Shared on August 6, 2010 at 6:25 am By:
Parkinson's Disease: TEMPO study added support for Azilect in PD patients: Teva Pharmaceutical Industries Ltd. and... http://bit.ly/af7fuX
Lundbeck and Teva launch Azilect in France | InPharm
inpharm.com — “Lundbeck and Teva launch Azilect in France | InPharm” View full resource at inpharm.com
Most Recently Shared on January 20, 2010 at 8:45 am By:
Pharmafocus Pharma and Health News
Lundbeck and Teva launch Parkinson’s drug Azilect in France. http://ow.ly/YudG
Azilect Prescribing Information updated to reflect reduced medication and food restrictions - MPR
empr.com — “Teva Pharmaceuticals announced that the FDA has approved revised Prescribing Information for Azilect (rasagiline tablets) reducing medication and food restrictions.” View full resource at empr.com
Most Recently Shared on December 15, 2009 at 3:55 pm By:
MPR News: Azilect Prescribing Information updated to reflect reduced medication and food restrictions: Teva Pharmac... http://bit.ly/7ZRfh4
Study confirms Azilect as a selective MAO-B inhibitor
news-medical.net — “Teva Neuroscience Inc. today announced the publication of a study demonstrating the selectivity of Azilect® (rasagiline tablets) for inhibition of MAO-B (monoamine oxidase-B) at the maximum approved dose of 1 mg/day. The data was published in the Journal of Clinical Pharmacology OnlineFirst on May 5, 2010.” View full resource at news-medical.net
Most Recently Shared on June 4, 2010 at 11:52 am By:
Medicare News: Study confirms Azilect as a selective MAO-B inhibitor: Teva Neuroscience Inc. today announced the p... http://bit.ly/9HHPMA
Pharmacy Europe - Study demonstrates benefits of Azilect® in Parkinson's disease
pharmacyeurope.net — “Pharmacy Europe, daily news for pharmacists, hundreds of clinical and best practice articles, online comment and video presentations.” View full resource at pharmacyeurope.net
Most Recently Shared on August 6, 2010 at 6:45 pm By:
Study demonstrates benefits of Azilect® in Parkinson's disease: Long-term data has been published from the TEMPO ... http://bit.ly/9TU4xR
Teva Pharmaceutical Industries receives approval for newly revised prescribing information for AZILECT
news-medical.net — “Teva Pharmaceutical Industries, Ltd. today announced the U.S. Food and Drug Administration (FDA) approved the newly revised prescribing information for AZILECT® (rasagiline tablets) reducing medication and food restrictions.” View full resource at news-medical.net
Most Recently Shared on December 15, 2009 at 9:57 pm By:
Parkinson's Disease: Teva Pharmaceutical Industries receives approval for newly revised prescribing information for... http://bit.ly/4A228i
FDA Approves Newly Revised Prescribing Information for Azilect Reducing Medication and Food Restrictions
drugs.com — “Azilect (rasagiline) is used for Parkinson’s Disease. Information from Drugs.com includes Azilect side effects, interactions and indications.” View full resource at drugs.com
Most Recently Shared on December 15, 2009 at 10:13 pm By:
FDA Approves New Prescribing Information for Azilect Reducing Medication and Food Restrictions - http://bit.ly/8BJT52
FDA Approves Newly Revised Prescribing Information For AZILECT(R) Reducing Medication And Food Restrictions
medicalnewstoday.com — “Teva Pharmaceutical Industries, Ltd. (NASDAQ: TEVA) announced the U.S. Food and Drug Administration (FDA) approved the newly revised prescribing information for AZILECT® (rasagiline tablets) r” View full resource at medicalnewstoday.com
Most Recently Shared on December 15, 2009 at 8:11 pm By:
MNT Parkinson's News Health News
FDA Approves Newly Revised Prescribing Information For AZILECT(R) Reducing Medication And Food Restrictions http://mnt.to/3vwn
TEMPO Extentension Study Further Demonstrates The Benefits Of Azilect® In Early Parkinson's Disease Patients
medicalnewstoday.com — “Teva Pharmaceutical Industries Ltd. and H. Lundbeck A/S have announced newly published long-term data on Azilect® (rasagiline tablets) from the TEMPO study and its open-label extension. The fi” View full resource at medicalnewstoday.com
Most Recently Shared on August 6, 2010 at 8:05 pm By:
MNT Parkinson's News Health News
TEMPO Extentension Study Further Demonstrates The Benefits Of Azilect® In Early Parkinson's Disease Patients http://mnt.to/3H6Y
TEMPO Study Further Demonstrates The Benefits Of Azilect® In Early Parkinson's Disease Patients
medicalnewstoday.com — “H. Lundbeck A/S (Lundbeck) and Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced newly published long-term data on Azilect® (rasagiline tablets) from the TEMPO study and its open-” View full resource at medicalnewstoday.com
Most Recently Shared on August 9, 2010 at 2:00 pm By:
MNT Parkinson's News Health News
TEMPO Study Further Demonstrates The Benefits Of Azilect® In Early Parkinson's Disease Patients http://mnt.to/3H8W #parkinsons
Results Of ADAGIO Study With AZILECT(R) In Parkinson's Disease Published In New England Journal Of Medicine
medicalnewstoday.com — “Results from the ADAGIO trial, published online today in The New England Journal of Medicine, demonstrated that Parkinson's disease patients receiving AZILECT® (rasagiline) 1mg/day at t” View full resource at medicalnewstoday.com
Most Recently Shared on September 24, 2009 at 5:55 pm By:
MNT Parkinson's News Health News
Results Of ADAGIO Study With AZILECT(R) In Parkinson's Disease Published In New England Journal Of Medicine: Res.. http://bit.ly/jrVBZ
Parkinson's in the Media: Watson in patent dispute over Teva's Azilect | Parkinson's Action Network
parkinsonsaction.org — “Parkinson's in the Media: Watson in patent dispute over Teva's Azilect | Parkinson's Action Network” View full resource at parkinsonsaction.org
Most Recently Shared on October 6, 2010 at 5:12 pm By:
Parkinson'sAction Health Organization
Parkinson's in the Media: Watson in patent dispute over Teva's Azilect http://dlvr.it/6cp2Y
Parkinson's in the Media: Teva sues Apotex for Azilect patent infringement | Parkinson's Action Network
parkinsonsaction.org — “Parkinson's in the Media: Teva sues Apotex for Azilect patent infringement | Parkinson's Action Network” View full resource at parkinsonsaction.org
Most Recently Shared on June 13, 2011 at 5:02 pm By:
Parkinson'sAction Health Organization
Parkinson's in the Media: Teva sues Apotex for Azilect patent infringement http://dlvr.it/W9qz5
Parkinson's UK - Study claims earlier treatment with Azilect can slow Parkinson's progression - (formerly Parkinson's Disease Society)
parkinsons.org.uk — “Results of a clinical study suggest that earlier treatment with the drug Azilect (rasagiline) can slow the progression of the condition for people with newly diagnosed Parkinson's” View full resource at parkinsons.org.uk
Most Recently Shared on September 24, 2009 at 12:39 pm By:
Parkinson's UK Health Organization and Research
Study claims earlier treatment with Azilect can slow Parkinson's progression http://bit.ly/3Fkiun
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Related WisdomCards
Featuring the top 3 experts for this topic
-
WebMD_News
The leading source for trustworthy and timely health news and information.
-
News-Medical.Net
Stay up to date with the latest Parkinson's Disease news and research via News-Medical.Net
-
Pharmafocus
Monthly pharmaceutical, biotech & healthcare news publication for Europe. For pharma & biotech jobs follow @inpharmjobs. Twitter accounts run by @dominic_tyer
Advertisement
